Topic 7: What Earlier Recognition Changes
Earlier recognition allows the care team to:
- Name the chronic disease rather than repeatedly labeling individual lesions.
- Document baseline inflammatory activity, structural findings, involved regions, and patient burden.
- Provide accurate education and reduce stigma or self-blame.
- Address pain, drainage, wound care, and functional needs.
- Screen for relevant comorbidities and psychosocial concerns according to clinical context.
- Avoid reflexively repeating ineffective acute treatment.
- Arrange appropriate follow-up and dermatology referral when diagnosis is uncertain, disease is clinically significant, or control is inadequate.
A retrospective multicenter study of adalimumab-treated patients found that shorter diagnostic delay and shorter disease duration were associated with a greater likelihood of clinical response, supporting the concept of a treatment window. Because the study was observational and involved a selected treated population, it supports earlier action but does not prove that one timing threshold applies to every patient.8
A 2026 expert framework similarly proposes identifying clinically meaningful moderate disease before extensive irreversible damage develops. This remains an expert framework rather than a universally adopted definition and will be explored in greater depth in Part 6.9
Practical Recognition-to-Action Sequence
Step 1: Recognize the pattern. Recurrent typical lesions in characteristic locations should prompt consideration of HS.
Step 2: Reconstruct the course. Ask about onset, flare frequency, other locations, drainage, scars, procedures, and treatments.
Step 3: Assess significance. Document inflammatory activity, structural disease, pain, function, and quality-of-life effects.
Step 4: Respond to current needs. Address acute symptoms while avoiding a purely episodic care plan.
Step 5: Create continuity. Arrange follow-up, document the suspected or confirmed diagnosis clearly, and refer or escalate when appropriate.